Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 46.43
CLDX's Cash to Debt is ranked higher than
50% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: 46.43 vs. CLDX: 46.43 )
Ranked among companies with meaningful Cash to Debt only.
CLDX' s Cash to Debt Range Over the Past 10 Years
Min: 2.95  Med: 142.9 Max: No Debt
Current: 46.43
Equity to Asset 0.86
CLDX's Equity to Asset is ranked higher than
77% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CLDX: 0.86 )
Ranked among companies with meaningful Equity to Asset only.
CLDX' s Equity to Asset Range Over the Past 10 Years
Min: -0.32  Med: 0.83 Max: 0.94
Current: 0.86
-0.32
0.94
Interest Coverage No Debt
CLDX's Interest Coverage is ranked higher than
96% of the 458 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CLDX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
CLDX' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: No Debt
N/A
No Debt
F-Score: 3
Z-Score: 2.04
M-Score: -1.36
WACC vs ROIC
22.87%
-1063.42%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -1961.82
CLDX's Operating margin (%) is ranked lower than
83% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -78.20 vs. CLDX: -1961.82 )
Ranked among companies with meaningful Operating margin (%) only.
CLDX' s Operating margin (%) Range Over the Past 10 Years
Min: -3414.11  Med: -878.49 Max: -13.79
Current: -1961.82
-3414.11
-13.79
Net-margin (%) -1923.12
CLDX's Net-margin (%) is ranked lower than
84% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. CLDX: -1923.12 )
Ranked among companies with meaningful Net-margin (%) only.
CLDX' s Net-margin (%) Range Over the Past 10 Years
Min: -3292.81  Med: -854.57 Max: -5.41
Current: -1923.12
-3292.81
-5.41
ROE (%) -48.81
CLDX's ROE (%) is ranked lower than
60% of the 878 Companies
in the Global Biotechnology industry.

( Industry Median: -33.45 vs. CLDX: -48.81 )
Ranked among companies with meaningful ROE (%) only.
CLDX' s ROE (%) Range Over the Past 10 Years
Min: -2929.64  Med: -67.06 Max: -3.4
Current: -48.81
-2929.64
-3.4
ROA (%) -42.54
CLDX's ROA (%) is ranked lower than
61% of the 971 Companies
in the Global Biotechnology industry.

( Industry Median: -29.51 vs. CLDX: -42.54 )
Ranked among companies with meaningful ROA (%) only.
CLDX' s ROA (%) Range Over the Past 10 Years
Min: -120  Med: -41.12 Max: -2.02
Current: -42.54
-120
-2.02
ROC (Joel Greenblatt) (%) -1125.75
CLDX's ROC (Joel Greenblatt) (%) is ranked lower than
63% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: -372.06 vs. CLDX: -1125.75 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CLDX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1156.55  Med: -521.57 Max: -10.72
Current: -1125.75
-1156.55
-10.72
Revenue Growth (3Y)(%) -33.90
CLDX's Revenue Growth (3Y)(%) is ranked lower than
81% of the 482 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. CLDX: -33.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CLDX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -67.2  Med: -23.5 Max: 105.6
Current: -33.9
-67.2
105.6
EBITDA Growth (3Y)(%) 10.40
CLDX's EBITDA Growth (3Y)(%) is ranked higher than
63% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.50 vs. CLDX: 10.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CLDX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -32.2  Med: -2.4 Max: 22.5
Current: 10.4
-32.2
22.5
EPS Growth (3Y)(%) 8.70
CLDX's EPS Growth (3Y)(%) is ranked higher than
66% of the 511 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. CLDX: 8.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CLDX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -64.6  Med: -6.9 Max: 161.6
Current: 8.7
-64.6
161.6
» CLDX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

CLDX Guru Trades in Q4 2015

Paul Tudor Jones 15,857 sh (New)
Columbia Wanger 3,610,008 sh (+16.09%)
First Eagle Investment 579,542 sh (+3.57%)
Murray Stahl 26,335 sh (unchged)
» More
Q1 2016

CLDX Guru Trades in Q1 2016

John Paulson 70,800 sh (New)
Jim Simons 813,331 sh (New)
Paul Tudor Jones 139,437 sh (+779.34%)
First Eagle Investment 629,542 sh (+8.63%)
Murray Stahl 26,335 sh (unchged)
Columbia Wanger 2,976,400 sh (-17.55%)
» More
Q2 2016

CLDX Guru Trades in Q2 2016

Columbia Wanger 5,261,934 sh (+76.79%)
Murray Stahl 26,335 sh (unchged)
John Paulson 70,800 sh (unchged)
Jim Simons 776,800 sh (-4.49%)
First Eagle Investment 445,000 sh (-29.31%)
Paul Tudor Jones 15,137 sh (-89.14%)
» More
Q3 2016

CLDX Guru Trades in Q3 2016

Jim Simons 1,258,214 sh (+61.97%)
Murray Stahl 26,335 sh (unchged)
John Paulson 70,800 sh (unchged)
First Eagle Investment 445,000 sh (unchged)
Paul Tudor Jones 13,406 sh (-11.44%)
Columbia Wanger 2,907,523 sh (-44.74%)
» More
» Details

Insider Trades

Latest Guru Trades with CLDX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:FLML, NAS:CLSD, NAS:MCRB, NAS:BCRX, NAS:VSAR, NAS:CTMX, NAS:PTGX, NAS:PTCT, NAS:CRIS, NAS:AGEN, NAS:PDLI, NAS:SELB, NAS:NSTG, NAS:NERV, NAS:XBIT, OTCPK:HNSBF, NAS:TLGT, NAS:CYNA, NAS:CYTK, NAS:BOLD » details
Traded in other countries:TCE1.Germany,
Celldex Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the development, manufacturing and commercialization of immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases.

Celldex Therapeutics Inc was incorporated in Delaware. The Company is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. Its drug candidates are derived from a broad set of complementary technologies which have the ability to utilize the human immune system and enable the creation of therapeutic agents. It is using these technologies to develop targeted immunotherapeutics comprised of protein-based molecules such as vaccines, antibodies and antibody-drug conjugates that are used to treat specific types of cancer or other diseases. Its stage drug candidate, Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine in clinical studies for the treatment of glioblastoma patients that express a specific cancer marker known as EGFRvIII. Glembatumumab vedotin (also referred to as CDX-011) is a targeted antibody-drug conjugate in a randomized, Phase 2b study for the treatment of triple negative breast cancer and a Phase 2 study for the treatment of metastatic melanoma. Varlilumab (also referred to as CDX-1127) is an immune modulating antibody that is designed to enhance a patient's immune response against their cancer. It established proof of concept in a Phase 1 study with varlilumab, which has allowed several combination studies to begin in various indications. The Company is a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for patients with unmet medical needs. Its clinical development programs include Rintega, Glembatumumab vedotin, Varlilumab, CDX-1401, CDX-301, CDX-014. The Company relies on contract manufacturing organizations, or CMOs, to manufacture drug substance and drug product for its late-stage clinical studies of Rintega and glembatumumab vedotin as well as for future commercial supplies. It also relies on CMOs for filling and packaging, labeling, storage and shipping of drug product. The Company own or license rights under more than 300 granted patents and national and regional patent applications in the U.S. and in international territories covering inventions relating to its business. Competitors that the Company is aware of that have initiated a Phase 3 study or have obtained marketing approval for a potential competitive drug/device for Rintega in the treatment of glioblastoma and/or glembatumumab vedotin in the treatment of breast cancer include AbbVie, Arbor Pharmaceutics, Inc., AstraZeneca PLC, Bayer, Bristol-Myers Squibb, Celgene Corporation, Eisai Inc., Eli Lilly and Company, Medigene AG, Northwest Biotherapeutics, Inc., Novartis, Novocure, Pfizer Inc., and Roche.

Ratios

vs
industry
vs
history
P/B 1.82
CLDX's P/B is ranked higher than
78% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. CLDX: 1.82 )
Ranked among companies with meaningful P/B only.
CLDX' s P/B Range Over the Past 10 Years
Min: 1.23  Med: 5.15 Max: 50.74
Current: 1.82
1.23
50.74
P/S 58.97
CLDX's P/S is ranked lower than
80% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 10.41 vs. CLDX: 58.97 )
Ranked among companies with meaningful P/S only.
CLDX' s P/S Range Over the Past 10 Years
Min: 1.67  Med: 43.2 Max: 975.38
Current: 58.97
1.67
975.38
EV-to-EBIT -1.54
CLDX's EV-to-EBIT is ranked lower than
99.99% of the 252 Companies
in the Global Biotechnology industry.

( Industry Median: 19.98 vs. CLDX: -1.54 )
Ranked among companies with meaningful EV-to-EBIT only.
CLDX' s EV-to-EBIT Range Over the Past 10 Years
Min: -77.2  Med: -4.1 Max: 0.3
Current: -1.54
-77.2
0.3
EV-to-EBITDA -1.59
CLDX's EV-to-EBITDA is ranked lower than
99.99% of the 276 Companies
in the Global Biotechnology industry.

( Industry Median: 16.24 vs. CLDX: -1.59 )
Ranked among companies with meaningful EV-to-EBITDA only.
CLDX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -515.4  Med: -3.8 Max: 39.2
Current: -1.59
-515.4
39.2
Current Ratio 11.26
CLDX's Current Ratio is ranked higher than
80% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. CLDX: 11.26 )
Ranked among companies with meaningful Current Ratio only.
CLDX' s Current Ratio Range Over the Past 10 Years
Min: 0.56  Med: 6.85 Max: 17.22
Current: 11.26
0.56
17.22
Quick Ratio 11.26
CLDX's Quick Ratio is ranked higher than
81% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.94 vs. CLDX: 11.26 )
Ranked among companies with meaningful Quick Ratio only.
CLDX' s Quick Ratio Range Over the Past 10 Years
Min: 0.56  Med: 6.85 Max: 17.22
Current: 11.26
0.56
17.22
Days Sales Outstanding 85.98
CLDX's Days Sales Outstanding is ranked lower than
67% of the 601 Companies
in the Global Biotechnology industry.

( Industry Median: 61.72 vs. CLDX: 85.98 )
Ranked among companies with meaningful Days Sales Outstanding only.
CLDX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 1.43  Med: 38.85 Max: 89.44
Current: 85.98
1.43
89.44

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -15.30
CLDX's 3-Year Average Share Buyback Ratio is ranked lower than
61% of the 555 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. CLDX: -15.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CLDX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -73.1  Med: -26.5 Max: 0
Current: -15.3
-73.1
0

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.38
CLDX's Price/Net Cash is ranked higher than
84% of the 518 Companies
in the Global Biotechnology industry.

( Industry Median: 6.05 vs. CLDX: 2.38 )
Ranked among companies with meaningful Price/Net Cash only.
CLDX' s Price/Net Cash Range Over the Past 10 Years
Min: 1.76  Med: 7.47 Max: 47.3
Current: 2.38
1.76
47.3
Price/Net Current Asset Value 2.28
CLDX's Price/Net Current Asset Value is ranked higher than
84% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 5.53 vs. CLDX: 2.28 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CLDX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.7  Med: 6.65 Max: 1163
Current: 2.28
1.7
1163
Price/Tangible Book 2.12
CLDX's Price/Tangible Book is ranked higher than
79% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. CLDX: 2.12 )
Ranked among companies with meaningful Price/Tangible Book only.
CLDX' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.62  Med: 6.01 Max: 54.69
Current: 2.12
1.62
54.69
Price/Median PS Value 1.37
CLDX's Price/Median PS Value is ranked lower than
67% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 0.93 vs. CLDX: 1.37 )
Ranked among companies with meaningful Price/Median PS Value only.
CLDX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.04  Med: 0.79 Max: 29.23
Current: 1.37
0.04
29.23
Earnings Yield (Greenblatt) (%) -65.19
CLDX's Earnings Yield (Greenblatt) (%) is ranked lower than
90% of the 942 Companies
in the Global Biotechnology industry.

( Industry Median: -8.50 vs. CLDX: -65.19 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CLDX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -460.4  Med: 391.85 Max: 1732
Current: -65.19
-460.4
1732

More Statistics

Revenue (TTM) (Mil) $6.70
EPS (TTM) $ -1.29
Beta2.75
Short Percentage of Float26.75%
52-Week Range $2.85 - 17.30
Shares Outstanding (Mil)101.25

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 5 3 3 20
EPS ($) -1.31 -1.29 -1.36 -1.17
EPS w/o NRI ($) -1.31 -1.29 -1.36 -1.17
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NAS:CLDX

Headlines

Articles On GuruFocus.com
Cantor Fitzgerald and Brean Capital Positive on Celldex Therapeutics Following Positive Data For Bra Jun 01 2015 
Monday Morning Pre-Market Insights: Celldex Therapeutics, Celladon Corp, CTI BioPharma Corp, TG Ther Jun 01 2015 
Roth Capital Weighs In On 5 Biotech Stocks to Watch Apr 05 2015 
Cowen & Co Remains Bullish on Celldex Therapeutics Following FDA 'Breakthrough' Approval Feb 24 2015 
CLDX up 223%, Cohen Gains Big Apr 23 2013 
Steve Cohen Increases Celldex Up 145% Apr 06 2013 
5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
CELLDEX THERAPEUTICS, INC (CLDX) CEO Anthony S Marucci buys 12,000 Shares Sep 13 2010 
Weekly CFO Buys Highlight: GNMK, RTIX, BKOR, PTEK, CLDX Sep 12 2010 
CELLDEX THERAPEUTICS, INC Reports Operating Results (10-Q) Aug 05 2010 

More From Other Websites
CELLDEX THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation... Dec 05 2016
Theresa LaVallee, Ph.D., Joins Celldex Therapeutics’ Senior Management Team Dec 05 2016
Celldex Presents Data on CDX-1140, a Novel CD40 Agonist Antibody for Hematologic and Solid... Dec 05 2016
8:01 am Celldex Therapeutics presents data on CDX-1140, a novel cd40 agonist antibody for... Dec 05 2016
Celldex Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CLDX-US :... Dec 01 2016
CELLDEX THERAPEUTICS, INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets,... Nov 29 2016
Celldex Therapeutics Completes Acquisition of Kolltan Pharmaceuticals Nov 29 2016
ETFs with exposure to Celldex Therapeutics, Inc. : November 23, 2016 Nov 23 2016
Celldex Therapeutics, Inc. :CLDX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 22, 2016 Nov 22 2016
CELLDEX THERAPEUTICS, INC. Financials Nov 17 2016
Celldex Cancer Drug Did Well in Early Trial (CLDX) Nov 15 2016
Celldex Stock Up on Positive Data on New Cancer Candidate Nov 15 2016
Celldex Presents Data on New Product Candidate, CDX-1140, a Novel CD40 Agonist Antibody Nov 14 2016
Celldex Presents Data on New Product Candidate, CDX-1140, a Novel CD40 Agonist Antibody Nov 14 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)